Who we are
Profile & History
Unicorns Pharmaceuticals was incorporated in 2004, as a privately held medium scale company engaged in manufacture facility of pharmaceutical formulations for the global market. Our state of the art plant, which conforms to stringent cGMP and WHO compliance certified company guidelines facilitates production of a wide range of advanced and finished dosage forms. We have laid thrust on contract research and customer oriented manufacturing system.
We at Unicorns Pharmaceuticals are focused on providing exceptional quality products and services to fulfill the growing consumer health products market. We are strong in Domestic Market past 21 years
At Unicorns Pharmaceuticals we are focused on providing products and services of exceptional quality to fulfill the growing Consumer health market especially in developing countries.- We are following the “Good Manufacturing practices” as prescribed of W.H.O. guidelines.
- We are investing significantly more in upgrading and expanding our exporting capabilities.
- Unique strategic partnering opportunities, overseas expansion and additional acquisition opportunities are all important parts of our strategic plans to drive and sustain profitable growth into the future.
People, Progress, Purpose & Social Responsibility
Consistent growth and sustainability is a multidimensional aspiration for all at Unicorns, we remain focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance.
Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 2004. Unicorns is focused on increasing the momentum in the business through organic growth routes. Growth is well spread across geographies with focus on key therapeutics segments. We continue to evaluate various therapy areas to strengthen its business and competitiveness. Unicorns has forayed into high growth potential segments like Cardiovascular, Diabetes,Neuro, Anti Biotics, Anti Fungal, Pain management, Beta Lactam and general products. These new growth areas will add significant depth to the existing product pipeline.
Key Fact
- Units : 2 manufacturing Sites.
- Products : Capability to manufacture all dosage forms and all therapeutic categories.
- Sale bifurcation : 1/3rds of the business comes from India and the remaining 2/3rd from overseas markets.
Accreditations
